Associated Papers
Plasma oxysterols: biomarkers for diagnosis and treatment in spastic paraplegia type 5.
Marelli C et al.
Brain : a Journal of Neurology, 2018
Hereditary spastic paraplegia type 5: natural history, biomarkers and a randomized controlled trial.
Schöls L et al.
Brain : a Journal of Neurology, 2017
Amplicon-based high-throughput pooled sequencing identifies mutations in CYP7B1 and SPG7 in sporadic spastic paraplegia patients.
Schlipf NA et al.
Clinical Genetics, 2011
Marked accumulation of 27-hydroxycholesterol in SPG5 patients with hereditary spastic paresis.
Schüle R et al.
Journal of Lipid Research, 2010
Analysis of CYP7B1 in non-consanguineous cases of hereditary spastic paraplegia.
Schüle R et al.
Neurogenetics, 2009
Select a paper to view details